Compare Incyte Corporation (INCY) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Synchrony Financial — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Synchrony Financial trades at $72.45 (market cap $24.69B). The key difference: Incyte Corporation and Synchrony Financial are close in size by market cap, and Synchrony Financial pays a 1.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SYF | |
|---|---|---|
Market Cap | $23.11B | $24.69B |
Sector | Health | Financials |
52-Week High | $118.52 | $88.47 |
52-Week Low | $67.38 | $63.78 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Synchrony Financial (SYF) trades at $73.41, down 0.29% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 7.62, net income margin of 24.06%, and consistent earnings beats. Recent corporate actions include a $0.30 dividend payment in May 2026. Cash flow remains positive despite projected 2026 challenges. Technical indicators show mixed signals with RSI at neutral levels but bearish moving averages.
SYF presents value opportunity with attractive valuation metrics and strong profitability, though facing near-term technical headwinds. Key risks include economic sensitivity as a consumer lender and potential margin pressure from rising rates. Analyst consensus remains bullish with $86.38 price target representing 17.7% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
